Cargando…

Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?

Gliomas are characterised by local infiltration, migration of tumour cells across long distances and sustained angiogenesis; therefore, proteins involved in these processes are most likely important. Such candidates are semaphorins involved in axon guidance and cell migration. In addition, semaphori...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karayan-Tapon, L, Wager, M, Guilhot, J, Levillain, P, Marquant, C, Clarhaut, J, Potiron, V, Roche, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567090/ https://www.ncbi.nlm.nih.gov/pubmed/18781179 http://dx.doi.org/10.1038/sj.bjc.6604641

Ejemplares similares

Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study
por: Wager, M, et al.
Publicado: (2008)

A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells
por: Barr, M P, et al.
Publicado: (2005)

Prognostic value of increase in transcript levels of Tp73 ΔEx2-3 isoforms in low-grade glioma patients
por: Wager, M, et al.
Publicado: (2006)

The status of CDKN2A alpha (p16(INK4A)) and beta (p14(ARF)) transcripts in thyroid tumour progression
por: Ferru, A, et al.
Publicado: (2006)

Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation
por: Sadanandam, A, et al.
Publicado: (2012)

VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo
por: Rennel, E S, et al.
Publicado: (2009)

Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells
por: Wey, J S, et al.
Publicado: (2005)

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression
por: Couvelard, A, et al.
Publicado: (2005)

Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy
por: Zlobec, I, et al.
Publicado: (2008)

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma
por: Patard, J-J, et al.
Publicado: (2009)

Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma
por: Pritchard-Jones, R O, et al.
Publicado: (2007)

HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium
por: Kurosu, T, et al.
Publicado: (2011)

Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours
por: Salto-Tellez, M, et al.
Publicado: (2007)

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
por: Kut, C, et al.
Publicado: (2007)

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
por: Gavalas, N G, et al.
Publicado: (2012)

Isolation of tumour stem-like cells from benign tumours
por: Xu, Q, et al.
Publicado: (2009)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer
por: Gujam, F J A, et al.
Publicado: (2015)

Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype
por: Barathova, M, et al.
Publicado: (2008)

PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness
por: Molleví, D G, et al.
Publicado: (2008)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers
por: Shao, R, et al.
Publicado: (2011)

Oncofoetal fibronectin – a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma
por: Hesse, E, et al.
Publicado: (2005)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion
por: Bhattacharya, Rajat, et al.
Publicado: (2017)

Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer
por: Deans, D A C, et al.
Publicado: (2006)

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
por: Pinato, D J, et al.
Publicado: (2014)

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
por: Trinh, X B, et al.
Publicado: (2009)

Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases
por: Kahlert, C, et al.
Publicado: (2014)

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
por: Alfaro, C, et al.
Publicado: (2009)

Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
por: Pagin, A, et al.
Publicado: (2013)

Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast
por: Hasebe, T, et al.
Publicado: (2011)

Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells
por: Yamamoto, K, et al.
Publicado: (2012)

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer
por: Nalwoga, H, et al.
Publicado: (2010)

Expression of Semaphorin 3A and Neuropilin 1 in Asthma
por: Shim, Eun-Jin, et al.
Publicado: (2013)

Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome
por: Fangusaro, J R, et al.
Publicado: (2005)

Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation
por: Hiraoka, N, et al.
Publicado: (2010)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment
por: Ma, G-F, et al.
Publicado: (2014)

The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma
por: Dutta, S, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ioon9rfpqchip9u1hsds9ikgrp